liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Price-effectiveness: pharmacoeconomics, value and the right price for HPV vaccines
Linköping University, Department of Thematic Studies, Technology and Social Change. Linköping University, Faculty of Arts and Sciences.
2017 (English)In: Journal of Cultural Economy, ISSN 1753-0350, E-ISSN 1753-0369, Vol. 10, no 2, 163-177 p.Article in journal (Refereed) Published
Abstract [en]

Drawing on a pragmatist approach to pricing, this article discusses the impact of cost-effectiveness analysis (CEA) in the pricing strategies of pharmaceutical companies. Through an analysis of the human papillomavirus (HPV) vaccination, this article illustrates the strategic appropriation of evidence-based medicine (narratives and practices) that pharmaceutical companies have undertaken to enhance the value of their products. While governments are concentrated on the measurement of costs and efficiency (cost-effectiveness), companies attempt to find the threshold of effectiveness that supports their estimation of value. I have called such mode of calculation, price-effectiveness. Pharmaceutical companies engage in different ways with CEA in devising their own price strategies. First, CEA is used as an instrument to raise HPV vaccines as a matter of interest for health authorities. Second, companies produce models to maximise the effectiveness of their products. Third, the expense side of CEA has opened an opportunity to represent some conditions as diseases in order to increase the potential value of the vaccine, expressed in a higher price. Debates and practices of pricing offer a unique opportunity to trace how particular forms of quantification have become the common ground in the demonstration of value in healthcare and the adaptation of companies.

Place, publisher, year, edition, pages
ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD , 2017. Vol. 10, no 2, 163-177 p.
Keyword [en]
Pricing; value; vaccines; valuation; human papillomavirus vaccine
National Category
Social Sciences Interdisciplinary
Identifiers
URN: urn:nbn:se:liu:diva-138931DOI: 10.1080/17530350.2016.1260041ISI: 000402940600004OAI: oai:DiVA.org:liu-138931DiVA: diva2:1115796
Note

Funding Agencies|European Research Council [263657]

Available from: 2017-06-27 Created: 2017-06-27 Last updated: 2017-06-27

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Maldonado Castaneda, Oscar
By organisation
Technology and Social ChangeFaculty of Arts and Sciences
In the same journal
Journal of Cultural Economy
Social Sciences Interdisciplinary

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 78 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf